Project Grant R01HL169515

Award Date 6/17/24
Completion Date 5/31/28
Dollars Obligated $777K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) provides $480,990 to the University of Illinois to investigate the role of aerocytes, a specialized capillary endothelial cell population, in regulating alveolar epithelial regeneration following lung injury. The research aims to establish aerocytes as central regulators of alveolar regeneration, with a focus on the signaling...
This $773,446.00 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to better understand the early matricellular events in the injured lung and mechanisms critical for stabilizing the provisional matrix. The primary awardee, The Washington University, is leading this effort to identify targetable pathways for treating acute lung injury (ALI)/acute respiratory distress syndrome (ARDS)....
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $322,480 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the role of endothelial sphingosine-1-phosphate receptor 1 (S1PR1) in promoting lung repair after viral infections that lead to acute respiratory distress syndrome (ARDS). The research aims to define the...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will provide $704,795 to Baylor College of Medicine to develop a novel cell-based immunomodulation therapy to suppress lung inflammation and promote repair in acute respiratory distress syndrome (ARDS). The project will engineer retinal pigment epithelial (RPE) cells to produce therapeutic cytokines (IL-1RA, IL-10) and encapsulate them in alginate-based capsules for local...
This R01 project grant from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will investigate indole metabolites as novel danger signals that contribute to acute lung injury and acute respiratory distress syndrome (ARDS). The $688,163 award will fund research at the University of Pittsburgh over a 4-year period from September 2025 to May 2029. The key products and services to be delivered include: Determining the mechanism...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $2,168,857 to the University of Washington to conduct research focused on understanding the role of alveolar macrophage subsets in the pathobiology of acute respiratory distress syndrome (ARDS). The project aims to determine how the ontogeny and functional properties of different alveolar macrophage subsets contribute to ARDS clinical...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to investigate the role of the CARMIL1 protein in regulating pulmonary endothelial cell barrier function. The $495,159 award to the University of Illinois aims to characterize how CARMIL1 influences actin cytoskeleton dynamics and membrane protrusion, which are critical for maintaining the integrity of the pulmonary...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,220,472 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on using B cells to treat acute respiratory distress syndrome (ARDS) and associated neurological complications. The project aims to administer naive B cells to ameliorate inflammatory responses and promote tissue protection in a...
This R01 grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $607,952 to the University of Pittsburgh to investigate indole metabolites as novel danger signals that contribute to acute lung injury and the development of acute respiratory distress syndrome (ARDS). The project aims to determine the mechanisms by which indole metabolites derived from microbes induce regulated cell death pathways in lung...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program is focused on elucidating the factors and pathways that contribute to dysfunctional epithelial repair in pulmonary fibrosis. The $651,019 award to the Regents of the University of Michigan aims to identify aberrant epithelial cell states that impair alveolar regeneration and exacerbate fibrosis, with a particular emphasis on the role...

INDUCTION OF MYELOID-EPITHELIAL GAP JUNCTIONAL CHANNELS TO ENHANCE HOST RESILIENCE AGAINST ACUTE LUNG INJURY. - PROJECT SUMMARY SIGNIFICANCE. BETTER UNDERSTANDING IS REQUIRED OF INNATE MECHANISMS AND NEW CELL THERAPIES THAT ENHANCE HOST RESILIENCE AGAINST ACUTE LUNG INJURY (ALI), AND THE ASSOCIATED ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). BASED ON OUR PRIOR FINDINGS, OUR PREMISE IS THAT GAP JUNCTIONAL CHANNELS (GJCS) BETWEEN MYELOID CELLS AND THE ALVEOLAR EPITHELIUM (AE) DETERMINE HOST RESILIENCE TO ALI. HENCE, WE WILL FIRST, EVALUATE THE EXTENT TO WHICH INCREASING ALVEOLAR GJCS BETWEEN AIRWAY-INSTILLED BONE MARROW-DERIVED MONOCYTES (BMDMS) AND THE AE ENHANCES HOST RESILIENCE. SECOND, WE WILL EVALUATE THE ROLE OF GJC-COMMUNICATED CA2+ WAVES, LEADING TO ACTIVATION OF CALMODULIN KINASE KINASE-2 (CAMKK2) IN THE AE, AS MECHANISMS UNDERLYING HOST RESILIENCE. APPROACH. WE WILL STUDY MOUSE MODELS OF ALI, INDUCED BY INTRANASAL INSTILLATION OF LPS (LIPOPOLYSACCHARIDE), OR OF THE GRAM-NEGATIVE BACTERIA, PSEUDOMONAS AERUGINOSA (PA), AN OPPORTUNISTIC PATHOGEN THAT CAUSES ARDS. WE WILL EVALUATE THE PREMISE BY MEANS OF REAL-TIME CONFOCAL MICROSCOPY (RCM) OF LIVE MOUSE LUNGS, AS WELL AS OTHER GENERAL APPROACHES. IN SA1, WE WILL DETERMINE THE TIMING OF ALVEOLAR GJC FORMATION AFTER BMDM INSTILLATION, THE EXTENT TO WHICH THE BMDMS CONVERT TO AMS, AND THE IMPACT ON ALI AS QUANTIFIED BY OUR REPORTED ASSAYS. IN SA2, WE WILL QUANTIFY REAL-TIME CA2+ RESPONSES, CAMKK2 ACTIVATION AND THE ROLE THE KINASE'S TARGET, AMP KINASE (AMPK). THE STUDIES WILL INVOLVE GENETICALLY MODIFIED MICE, AND HUMAN LUNG SLICES, AND CONSIDERATION OF RIGOR, SEX AND HUMAN RELEVANCE. IMPACT. OUR STUDIES WILL FOR THE FIRST TIME, REVEAL THE IMPORTANCE OF ENHANCING GJCS BETWEEN ALVEOLAR MYELOID CELLS AND THE AE AS A MEANS TO BOLSTERING HOST RESILIENCE TO ALI. APPLICATION OF INSTILLED BMDMS WILL BE UNDERSTOOD AS NOVEL CELL THERAPY FOR ALI/ARDS. OUTSTANDINGLY NOVEL MECHANISTIC UNDERSTANDING WILL BE ACHIEVED REGARDING THE PATHOBIOLOGY OF HOST RESILIENCE AGAINST ALI.

Posted 6/17/24, 12:00 AM